Jens Helby

Dr. Jens Helby

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
MMMathis Mottelson
Mathis Mottelson
Andreas GlenthøjAndreas Glenthøj
Andreas Glenthøj
BNBørge Grønne Nordestgaard
Børge Grønne Nordestgaard
CEChristina Ellervik
Christina Ellervik
JPJesper Brix Petersen
Jesper Brix Petersen
JHJens Helby
Jens Helby
It is unclear whether risk of infection is increased in individuals with hereditary hemochromatosis and in individuals with low or high plasma iron, transferrin saturation, or ferritin. Therefore, we tested whether high and low iron, transferrin saturation, and ferritin are associated with risk of infections observationally and genetically through HFE genotypes. We studied 142 188 Danish general population individuals. Iron, transferrin saturation, and ferritin were measured in 136 656, 136 599, and 38 020 individuals, respectively. HFE was genotyped for C282Y and H63D in 132 542 individuals. Median follow-up after study enrollment was 8 years (range, 0-38) for hospital and emergency room admissions with infections (n = 20 394) using the National Patient Register, covering all Danish hospitals. Hazard ratios for any infection were 1.20 (95% confidence interval [CI], 1.12-1.28) and 1.14 (95% CI, 1.07-1.22) in individuals with plasma iron ≤5th or ≥95th percentile compared with individuals with iron from 26th to 74th percentiles. Findings for transferrin saturation were similar, whereas infection risk was not increased in individuals with ferritin ≤5th or ≥95th percentile. Hazard ratios in C282Y homozygotes vs noncarriers were 1.40 (95% CI, 1.16-1.68) for any infection, 1.69 (95% CI, 1.05-2.73) for sepsis, and 2.34 (95% CI, 1.41-3.90) for death from infectious disease. Risk of infection was increased in C282Y homozygotes with normal plasma iron, transferrin saturation, or ferritin, and in C282Y homozygotes without liver disease, diabetes, and/or heart failure. In summary, low and high plasma iron and transferrin saturation were independently associated with increased infection risk. C282Y homozygotes had increased risk of any infection, sepsis, and death from infections. Even C282Y homozygotes with normal iron, transferrin saturation, or ferritin, not currently recommended for genotyping, had increased infection risk.

26 July 2017 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JHJens Helby
Jens Helby
BNB. G. Nordestgaard
B. G. Nordestgaard
TBThomas Benfield
Thomas Benfield
SBS. E. Bojesen
S. E. Bojesen
Background: Individuals with atopic conditions may have increased susceptibility to infections outside the organs directly affected by their atopic condition.Objective: We tested the hypothesis that atopic conditions overall, and stratified by smoking history, are associated with increased risk of hospitalization for infections.Methods: We collected information on smoking history and self‐reported atopic conditions from 105 519 individuals from the general population and followed them for up to 23 years for infectious disease hospitalizations and deaths. For asthma, we focused on never smokers with asthma diagnosed before age 50 (early asthma) to minimize confounding by chronic obstructive pulmonary disease.Results: During follow‐up, 11 160 individuals had infections. Never smokers with early asthma versus no atopic conditions had significantly increased risks of any infection (hazard ratio 1.65; 95% confidence interval 1.40–1.94), pneumonia (2.44; 1.92–3.11) and any non‐respiratory tract infection (1.36; 1.11–1.67); results were similar in ever smokers. Never smokers with any asthma had significantly increased risks of any infection (1.44; 1.24–1.66) and pneumonia (1.99; 1.62–2.44). Neither atopic dermatitis (1.00; 0.91–1.10) nor hay fever (1.00; 0.93–1.07) was associated with risk of any infection. In never smokers, risk estimates for any infection were comparable between asthma and diabetes, as were the population attributable fractions of 2.2% for any asthma and 2.9% for diabetes.Conclusion: Early asthma was associated with significantly increased risks of any infection, pneumonia and any non‐respiratory tract infection in never and ever smokers. In never smokers, risk estimates as well as population attributable fractions for any infection were comparable between asthma and diabetes, suggesting that asthma may be a substantial risk factor for infections in the general population.

9 December 2024 in BMJ
Verified
Journal Article
Open access
PDF file
MMMathis Mottelson
Mathis Mottelson
JHJens Helby
Jens Helby
BNBørge Grønne Nordestgaard
Børge Grønne Nordestgaard
CEChristina Ellervik
Christina Ellervik
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
Andreas GlenthøjAndreas Glenthøj
Andreas Glenthøj
Objectives: To test whether haemochromatosis HFE C282Y homozygotes have increased risk of diabetes, liver disease, and heart disease even when they have normal plasma iron, transferrin saturation, or ferritin concentrations and to test whether C282Y homozygotes with diabetes, liver disease, or heart disease have increased mortality compared with non-carriers with these diseases. Design: Prospective cohort study. Setting: Three Danish general population cohorts: the Copenhagen City Heart Study, the Copenhagen General Population Study, and the Danish General Suburban Population Study. Participants: 132 542 individuals genotyped for the HFE C282Y and H63D variants, 422 of whom were C282Y homozygotes, followed prospectively for up to 27 years after study enrolment. Main outcome measure: Hospital contacts and deaths, retrieved from national registers, covering all hospitals and deaths in Denmark. Results: Comparing C282Y homozygotes with non-carriers, hazard ratios were 1.72 (95% confidence interval (CI) 1.24 to 2.39) for diabetes, 2.22 (1.40 to 3.54) for liver disease, and 1.01 (0.78 to 1.31) for heart disease. Depending on age group, the absolute five year risk of diabetes was 0.54-4.3% in C282Y homozygous women, 0.37-3.0% in non-carrier women, 0.86-6.8% in C282Y homozygous men, and 0.60-4.80% in non-carrier men. When studied according to levels of iron, transferrin saturation, and ferritin in a single blood sample obtained at study enrolment, risk of diabetes was increased in C282Y homozygotes with normal transferrin saturation (hazard ratio 2.00, 95% CI 1.04 to 3.84) or ferritin (3.76, 1.41 to 10.05) and in C282Y homozygotes with normal levels of both ferritin and transferrin saturation (6.49, 2.09 to 20.18). C282Y homozygotes with diabetes had a higher risk of death from any cause than did non-carriers with diabetes (hazard ratio 1.94, 95% CI 1.19 to 3.18), but mortality was not increased in C282Y homozygotes without diabetes. The percentage of all deaths among C282Y homozygotes that could theoretically be prevented if excess deaths in individuals with a specific disease were eliminated (the population attributable fraction) was 27.3% (95% CI 12.4% to 39.7%) for diabetes and 14.4% (3.1% to 24.3%) for liver disease. Risk of diabetes or liver disease was not increased in H63D heterozygotes, H63D homozygotes, C282Y heterozygotes, or C282Y/H63D compound heterozygotes. Conclusions: Haemochromatosis C282Y homozygotes with normal transferrin saturation and/or ferritin, not recommended for HFE genotyping according to most guidelines, had increased risk of diabetes. Furthermore, C282Y homozygotes with diabetes had higher mortality than non-carriers with diabetes, and 27.3% of all deaths among C282Y homozygotes were potentially attributable to diabetes. These results indicate that prioritising detection and treatment of diabetes in C282Y homozygotes may be relevant.

6 January 2025 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
FCFrederik Christensen
Frederik Christensen
Deniz Kenan KılıçDeniz Kenan Kılıç
Deniz Kenan Kılıç
Izabela NielsenIzabela Nielsen
Izabela Nielsen
TETarec Christoffer El-Galaly
Tarec Christoffer El-Galaly
Andreas GlenthøjAndreas Glenthøj
Andreas Glenthøj
AFAlexander Djupnes Fuglkjaer
Alexander Djupnes Fuglkjaer
Around 7% of the global population has congenital hemoglobin disorders, with over 300,000 new cases of α-thalassemia annually. Diagnosis is costly and inaccurate in low-income regions, often relying on complete blood count (CBC) tests. This study employs machine learning (ML) to classify α-thalassemia traits based on gender and CBC, exploring the effects of grouping silent- and non-carriers. The dataset includes 288 individuals with suspected α-thalassemia from Sri Lanka. It was classified using eleven discriminant formulae and nine ML models. Outliers were removed using Mahalanobis distance, and resampling was conducted with the synthetic minority oversampling technique (SMOTE) and SMOTE-nominal continuous (NC). The Mann-Whitney U test handled feature extraction and class grouping. ML performance was evaluated with eight criteria. The Ehsani formula achieved an area under the receiver operating characteristic curve (ROC-AUC) of 0.66 by grouping silent- and non-carriers. The convolutional neural network (CNN) without feature extraction demonstrated better performance, with an accuracy of 0.85, sensitivity of 0.8, specificity of 0.86, and ROC-AUC of 0.95/0.93 (micro/macro). Performance was maintained even without preprocessing. ML models outperformed classical discriminant formulae in classifying α-thalassemia using sex and CBC features. A larger dataset could enhance ML model generalization and the impact of feature extraction. Grouping silent- and non-carriers improved ML results, especially with resampling. The silent carriers were not separable from non-carriers regarding the available features.

30 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
Andreas GlenthøjAndreas Glenthøj
Andreas Glenthøj
EBEduard J. van Beers
Eduard J. van Beers
RWRichard van Wijk
Richard van Wijk
MRMinke A.E. Rab
Minke A.E. Rab
EGEvelyn Groot
Evelyn Groot
KKKevin H.M. Kuo
Kevin H.M. Kuo
Introduction: Membranopathies encompass haemolytic disorders arising from genetic variants in erythrocyte membrane proteins, including hereditary spherocytosis and stomatocytosis. Congenital dyserythropoietic anaemia type II (CDA II) is associated with theSEC23Bgene and can exhibit phenotypic similarities to membranopathies. Current treatment options for these conditions, apart from splenectomy, are primarily supportive. Mitapivat, a novel pyruvate kinase (PK) activator, has demonstrated efficacy in increasing haemoglobin levels and reducing haemolysis in patients with PK deficiency, thalassemia, sickle cell disease and a mouse model of hereditary spherocytosis.Methods and analyses: Safety and efficacy of mitapivatsulfate in adult patients with erythrocyte membranopathies (SATISFY) is a prospective, multicentre, single-arm phase two trial involving approximately 25 adult patients (≥18 years) diagnosed with a membranopathy or CDA II. During the 8-week dose escalation period, subjects will receive an initial dose of 50 mg mitapivat two times per day and may increase to 100 mg two times per day at week 4 based on the safety and changes in haemoglobin levels. Patients tolerating mitapivat well may be eligible to continue in two consecutive 24-week fixed dose periods.The primary objective of this study is to evaluate the safety of mitapivat, assessed through the occurrence of treatment-emergent adverse events. Secondary objectives include assessing the effects of mitapivat on haemoglobin levels, haemolysis, erythropoiesis, patient-reported outcome measures and spleen size.SATISFY aims to assess the safety and efficacy of mitapivat in adult patients with red blood cell membranopathies and CDA II, with the aim of establishing proof-of-concept in patients living with these rare conditions.Ethics and dissemination: NCT05935202/CTIS:2023-503271-24-01. Findings will be published in peer-reviewed journals.Trial registration number: Clinicaltrials.gov,NCT05935202. CTIS:2023-503271-24-01. Registered 07-July-2023. Protocol number: 2.1.https://clinicaltrials.gov/study/NCT05935202.

1 March 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JHJens Helby
Jens Helby
SPSøren Lykke Petersen
Søren Lykke Petersen
BKBrian Kornblit
Brian Kornblit
BNBørge G. Nordestgaard
Børge G. Nordestgaard
BMBo Kok Mortensen
Bo Kok Mortensen
HSHenrik Sengeløv
Henrik Sengeløv
After allogeneic hematopoietic cell transplantation (allo-HCT), transplanted cells rapidly undergo multiple rounds of division. This may cause extensive telomere attrition, which could potentially prohibit further cell division and lead to increased mortality. We therefore characterized the development in telomere length after nonmyeloablative allo-HCT in 240 consecutive patients transplanted because of hematologic malignancies and tested the hypothesis that extensive telomere attrition post-transplant is associated with low overall survival. Telomere length was measured using quantitative PCR in mononuclear cells obtained from donors and recipients pretransplant and in follow-up samples from recipients post-transplant. Telomere attrition at 9 to 15 months post-transplant was calculated as the difference between recipient telomere length at 9 to 15 months post-transplant and donor pretransplant telomere length, divided by donor pretransplant telomere length. Although allo-HCT led to shorter mean telomere length in recipients when compared with donors, recipients had longer mean telomere length 9 to 15 months post-transplant than they had pretransplant. When compared with donor telomeres, recipients with extensive telomere attrition at 9 to 15 months post-transplant had low overall survival (10-year survival from 9 to 15 months post-transplant and onward: 68% in the tertile with least telomere attrition, 57% in the middle tertile, and 39% in the tertile with most attrition; log-rank P = .01). Similarly, after adjusting for potential confounders, recipients with extensive telomere attrition had high all-cause mortality (multivariable adjusted hazard ratio, 1.84 per standard deviation of telomere attrition at 9 to 15 months post-transplant; 95% confidence interval, 1.25 to 2.72; P = .002) and high relapse-related mortality (subhazard ratio, 2.07; 95% confidence interval, 1.14 to 3.76; P = .02). Taken together, telomere attrition may be a clinically relevant marker for identifying patients at high risk of mortality.